Tivozanib for bile duct and gallbladder cancers after chemotherapy
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital clinical trials.
This Phase 1/2 trial tests tivozanib (a targeted anti-cancer drug) in people with bile duct or gallbladder cancer that cannot be removed by surgery and has already been treated with first-line chemotherapy. The study looks at how well the drug works and how safe it is in this setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct cancer or gallbladder cancer confirmed by pathology (biopsy/cells) — tumor samples may be reviewed or re-bio npsied
- Your cancer cannot be removed with surgery
- You already had at least one round of first-line chemotherapy
- Your cancer can be measured on scans (measurable disease) using RECIST version 1.1
- You are 18 or older and feel well enough for treatment (ECOG 0 to 2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
This trial tests whether giving a targeted medicine based on your tumor's genetic makeup, after surgery, can help prevent your bile duct or gallbladder cancer from coming back. It's a new approach that tries to match treatment to your specific cancer biology.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and a targeted therapy to shrink bile duct or gallbladder cancers that are advanced but might be removable with surgery. The goal is to see if this approach can make surgery possible and improve outcomes.
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
This trial tests a new drug called sacituzumab tirumotecan for people with advanced bile duct cancer that has grown after previous treatment. The drug targets a protein called TROP2 on cancer cells and may help shrink tumors or slow the disease.
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.